From diarrhea to obesity in prohormone convertase 1/3 deficiency: Age-dependent clinical, pathologic, and enteroendocrine characteristics

Journal of Clinical Gastroenterology

Volumn 47, Issue 10, 2013, Pages 834-843

  Bandsma, Robert H J ^a   Sokollik, Christiane ^a   Chami, Rose ^b   Cutz, Ernest ^b   Brubaker, Patricia L ^c   Hamilton, Jill K ^a   Perlman, Kusiel ^a   Zlotkin, Stanley ^a   Sigalet, David L ^d   Sherman, Philip M ^a   Martin, Martin G ^e   Avitzur, Yaron ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Divisions of Pathology   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

children; congenital diarrhea; enteroendocrine cells; insulin; malabsorption; obesity; prohormone convertase deficiency

Indexed keywords

CHROMOGRANIN A; GLUCAGON LIKE PEPTIDE 1; PROINSULIN; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 3; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; ELECTRON MICROSCOPY; ENTEROENDOCRINE CELL; ENZYME DEFICIENCY; FUNCTION TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPHAGIA; IMMUNOHISTOCHEMISTRY; INFANT; INSULIN RELEASE; INTESTINE CELL; MALABSORPTION; MALE; NEWBORN; OBESITY; PANCREAS ISLET BETA CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WEIGHT GAIN;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; DIARRHEA; ENDOCRINE SYSTEM DISEASES; ENTEROENDOCRINE CELLS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE TOLERANCE TEST; HOSPITALS, PEDIATRIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INSULIN; MALE; MICROSCOPY, ELECTRON; OBESITY; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84886531614     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a89fc8     Document Type: Article

References (36)

1. Seidah NG. The proprotein convertases, 20 years later. Methods Mol Biol. 2011;768:23-57
2. Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16:303-306
3. Jackson RS, Creemers JW, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003; 112:1550-1560
4. Farooqi IS, Volders K, Stanhope R, et al. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J Clin Endocrinol Metab. 2007;92:3369-3373
5. O'Rahilly S, Gray H, Humphreys PJ, et al. Brief report: Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med. 1995;333:1386-1390
6. Martin MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology. 2013;145:138-148
7. Zhu X, Orci L, Carroll R, et al. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A 2002;99: 10299-10304
8. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705
9. Burrin DG, Stoll B, Jiang R, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G1249-G1256
10. Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-7916
11. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr. 2006;26:391-411
12. Adeli K, Lewis GF. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol. 2008;19:221-228
13. Zhu X, Zhou A, Dey A, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 2002;99: 10293-10298
14. CDC Growth Charts, 2012. Available at: Http://www.cdc.gov/ growthcharts. Accessed on December 17, 2012
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470
16. Hartmann B, Johnsen AH, Orskov C, et al. Structure, measurement, and secretion of human glucagon-like peptide- 2. Peptides. 2000;21:73-80
17. Goossens L, Bouvry M, Vanhaesebrouck P, et al. Citrulline levels in a paediatric age group: Does measurement on dried blood spots have additional value? Clin Chim Acta. 2011;412:661-664
18. Ong KK, Petry CJ, Emmett PM, et al. Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia. 2004;47:1064-1070
19. Salgin B, Ong KK, Thankamony A, et al. Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J Clin Endocrinol Metab. 2012;97:3302-3309
20. Yeckel CW, Weiss R, Dziura J, et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab. 2004;89:1096-1101
21. Amin H, Holst JJ, Hartmann B, et al. Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics. 2008;121:e180-e186
22. Lahlou N, Landais P, De BD, et al. Circulating leptin in normal children and during the dynamic phase of juvenile obesity: Relation to body fatness, energy metabolism, caloric intake, and sexual dimorphism. Diabetes. 1997;46:989-993
23. Lechago J. Endocrine cells of the gastrointestinal tract. Endocrine Pathology. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1997:1463-1493
24. Hsieh J, Longuet C, Maida A, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 2009;137:997-1005
25. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol. 1997;273:R1965-R1971
26. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2004;286:G964-G972
27. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 2001;98:12497-12502
28. Tolessa T, Gutniak M, Holst JJ, et al. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest. 1998;102:764-774
29. Lloyd DJ, Bohan S, Gekakis N. Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Hum Mol Genet. 2006;15:1884-1893
30. Revers RR, Henry R, Schmeiser L, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984;33:762-770
31. Gao Q, Horvath TL. Neurobiology of feeding and energy expenditure. Annu Rev Neurosci. 2007;30:367-398
32. De SA, Salem V, Long CJ, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011;14:700-706
33. Rehfeld JF, Bundgaard JR, Hannibal J, et al. The cellspecific pattern of cholecystokinin peptides in endocrine cells versus neurons is governed by the expression of prohormone convertases 1/3, 2, and 5/6. Endocrinology. 2008;149: 1600-1608
34. Zhu X, Cao Y, Voogd K, et al. On the processing of proghrelin to ghrelin. J Biol Chem. 2006;281:38867-38870
35. Benzinou M, Creemers JW, Choquet H, et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet. 2008;40:943-945
36. Creemers JW, Choquet H, Stijnen P, et al. Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes. 2012;61:383-390 Diseases